SCHEMBL4304855

SCHEMBL4304855

Cc1c(F)cccc1NC(N)=O

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.59
ALDH1A1 P00352 4/20 0.53
GAA P10253 2/20 0.53
RAB9A P51151 4/20 0.50
KDM4E B2RXH2 3/20 0.50
NPC1 O15118 3/20 0.50
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
POLB P06746 1/20 0.46
AGER Q15109 1/20 0.45
CXCR2 P25025 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPT P10636 1/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2091236 0.85 SMN1; SMN2 (0.68) SMN1; SMN2ALDH1A1GAARAB9ANPC1
SCHEMBL11249510 0.84 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1GAARAB9AKDM4E
SCHEMBL863826 0.83 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1GAARAB9AKDM4E
SCHEMBL30002532 0.83 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1GAARAB9AKDM4E
SCHEMBL2091233 0.83 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1GAARAB9ANPC1
SCHEMBL157188 0.82 RAB9A (0.72) SMN1; SMN2ALDH1A1GAARAB9AKDM4E
SCHEMBL29757931 0.82 RAB9A (0.72) SMN1; SMN2ALDH1A1GAARAB9AKDM4E
SCHEMBL18550663 0.81 ALDH1A1 (0.61) SMN1; SMN2ALDH1A1GAAKDM4EMEN1
SCHEMBL1140606 0.81 MAPT (0.61) SMN1; SMN2ALDH1A1GAARAB9AKDM4E
SCHEMBL6185781 0.81 RAB9A (0.53) SMN1; SMN2ALDH1A1GAARAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010180-A2 IL-8 RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2009-01-07 EP claimed
WO-2007124423-A2 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2007-11-01 WO claimed
EP-3924055-A1 SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF Novartis AG (CH) 2021-12-22 EP disclosed
WO-2020165834-A1 SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2020-08-20 WO disclosed
EP-3068763-A1 HYDROBROMIDE SALT OFN-(4-CHLORO-2-HYDROXY-3-((3S)-3-PIPERIDINYLSULFONYL)PHENYL-N'-(3-FLUORO-2-METHYLPHENYL)UREA Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2016-09-21 EP disclosed
WO-2015071235-A1 HYDROBROMIDE SALT OFN-(4-CHLORO-2-HYDROXY-3-((3S)-3-PIPERIDINYLSULFONYL)PHENYL-N'-(3-FLUORO-2-METHYLPHENYL)UREA GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2015-05-21 WO disclosed
EP-2010180-A2 IL-8 RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2009-01-07 EP disclosed
WO-2007124423-A2 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2007-11-01 WO disclosed
CN-1909908-A Pyrazolo [1, 5-a ] pyrimidin-7-yl-amine derivatives for the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2007-02-07 CN disclosed